Revivo Submits NIH Grant entitled “Advancement of Nomethiazole Therapeutics: The Development of a New Class of Procognitive and Disease Modifying Agents for Cognitive Decline”

Based on the existing science surrounding Nomethiazoles, Revivo Therapeutics completed an application for funding by the NIH in a SBIR grant proposal totaling over 3 million dollars. The Revivo Therapeutics team proposed a series of studies leading to the implementation of its Phase 1/2a studies of its reformulated product RIV-5061.